| Document |
Document Title |
|
WO/2024/097629A1 |
The present disclosure relates to compounds of Formula (I): or pharmaceutically acceptable salts or isotopically labeled derivatives thereof, wherein A is a 6- to 10- membered bridged bicyclic heterocycloalkyl comprising at least one oxy...
|
|
WO/2024/096389A1 |
The present invention relates to a composition for preventing, ameliorating or treating cognitive dysfunction or Alzheimer's disease comprising, as an active ingredient, Lactobacillus fermentum SRK414 strain which has accession number KC...
|
|
WO/2024/094150A1 |
Described herein are NOD-like receptor protein 3 (NLRP3) inflammasome inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder ass...
|
|
WO/2024/097868A1 |
This disclosure relates to the structure-- activity relationships for 4-phosphoryloxy-N,N-dimethyltryptamine (psilocybin), 4-phosphoryloxy-N-methyltryptamine (baeocystin), and 4-phosphoryloxy-N,N,N-trimethyltryptamine (aeruginascin), as ...
|
|
WO/2024/096133A1 |
The present invention provides a cell-to-cell human T-lymphotropic virus type 1 (HTLV-1) infection inhibitor that contains a substance that inhibits interaction between N-acetyllactosamine (LacNAc) and galectin-3 (Gal-3).
|
|
WO/2024/097327A1 |
The present invention features formulations and methods for the treatment of an emotional disorder or sexual dysfunction in a subject by administering to the subject a cannabinoid, such as (-)- trans-Δ8-tetrahydrocannabinol (delta-8-THC...
|
|
WO/2024/097063A1 |
In aspects, this invention covers crystalline forms of a soluble epoxide hydrolase inhibitor with ranges of properties advantageous for formulation and administration. In one aspect, the disclosure provides a method of treating a soluble...
|
|
WO/2024/092959A1 |
Provided are use of Coclaurine and a derivative thereof in improving NAMPT activity and a pharmaceutical composition. By screening for drug molecule monomers of natural products with NAMPT activation activity using a biological fluoresce...
|
|
WO/2024/073420A3 |
Methods and devices for the administration of compositions comprising glutathione trisulfide (GSSSG), pantethine trisulfide (PTN-SSS), or lipoic acid trisulfide (LA-SSS) to treat peripheral neuropathy, e.g., chemotherapy-induced peripher...
|
|
WO/2024/096445A1 |
The present invention relates to a composition for ameliorating, preventing, or treating stress and depression-related diseases, the composition containing talampanel. The talampanel in the present invention has excellent antidepressant ...
|
|
WO/2024/097737A1 |
The present disclosure relates to compositions and methods for treating blood vessel epicardial substance (BVES) protein-related disorders.
|
|
WO/2024/095144A1 |
The present application relates to lipidic nanoparticles that are suitable for the treatment of neurologic or chronic diseases. The lipidic nanoparticles of the present application are of the solid lipid nanoparticles or nanostructured l...
|
|
WO/2024/097945A1 |
The present technology is directed to a compound of Formula I: or a pharmaceutically acceptable salt and/or solvate thereof, and pharmaceutical compositions or medicaments comprising the compound. The compounds, pharmaceutical compositio...
|
|
WO/2024/094211A1 |
The present invention relates to mucosal drug delivery systems, and specifically to a lipid composition; the lipid composition containing a therapeutic agent and/or prophylactic agent such as RNA can be used for mucosal delivery of the t...
|
|
WO/2024/097251A1 |
In one aspect, the present disclosure describes methods which may be used to create ICWs and thereby regulate calcium signaling. These methods may employ a light-stimulated MM to generate an ICW and that ICW may be used to induce muscle ...
|
|
WO/2024/095906A1 |
The purpose of the present invention is to provide a composition or the like for preventing or inhibiting inflammation of neural cells. The present invention relates to a composition for preventing or inhibiting inflammation of neural ce...
|
|
WO/2024/095005A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, N-oxides, solvates and prodrugs thereof: wherein V, W, X, Y, Z, A1, A2, A3, A4, A5, A6, A7, A8, A9 and R3 are as defined in the specification,...
|
|
WO/2024/096124A1 |
The present disclosure provides a microorganism that inhibits oligomer formation of sgA. More specifically, the present disclosure provides a microorganism wherein at least one gene among the curli pili operon gene group, sigma factor ge...
|
|
WO/2024/097171A1 |
Disclosed herein are imidazole compounds and compositions useful in the treatment of a disease or disorder associated with sodium channel mediated activity, such as epilepsy, having the structures of Formulas (I)-(XV) wherein the R group...
|
|
WO/2024/096067A1 |
Provided is a cyclic peptide derivative composition for treating or preventing neuropathic pain and/or inflammatory pain. The present disclosure pertains to a composition containing: a compound for treating or preventing neuropathic pa...
|
|
WO/2024/097388A1 |
The present disclosure relates to methods of determining and administering a treatment course of action. In particular, the present disclosure relates to compositions and methods for monitoring and treating neurological damage (e.g., str...
|
|
WO/2024/097938A1 |
The present disclosure generally relates to compositions and methods for enhancing transportof molecules into the brain using modified IgG Fc regions, and methods of producing and using molecules comprising such modified Fc regions.
|
|
WO/2024/096280A1 |
The present invention relates to a composition for preventing, ameliorating, or treating Alzheimer's disease, comprising, as active ingredients, a Vitis vinifera stem extract and a compound isolated therefrom. The active ingredient of th...
|
|
WO/2024/097285A1 |
The present invention relates to compounds and methods useful for selectively modulating mTORC1 activity.
|
|
WO/2024/097391A1 |
4-Aminopyrrolo[2,I-f][1,2,4]triazine compounds of formula I for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of 4- aminopyrrolo[2,1-f][l,2,4]triazine compounds or ana...
|
|
WO/2024/094597A1 |
The invention relates to methods for the preparation of method of preparation of Tau aggregates, including fibrils, fibrillar species, soluble and insoluble oligomeric species, new Tau aggregates and uses thereof. The invention further r...
|
|
WO/2024/097798A1 |
The present invention provides anti-TREM2 antibodies, formulations thereof, and methods of use thereof.
|
|
WO/2024/096877A1 |
Intra-ocular injection of polymeric β(1,3; 1,6)-glucan (β-glucan) triggers a strong immune response in the eye. When combined with retro-orbital optic nerve crush injury (ONC), β-glucan promotes lengthy regeneration of severed retinal...
|
|
WO/2024/095133A1 |
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful a...
|
|
WO/2024/094216A1 |
A method for regulating and optimizing a ubiquitin proteasome system and/or an autophagy lysosome system in order to promote the degradation of intracellular and extracellular pathological proteins; a drug for promoting the degradation o...
|
|
WO/2024/093678A1 |
The invention relates to the field of pharmaceuticals. Specifically, the present application relates to a voltage-gated calcium ion channel α2δ subunit ligand comprising a polycyclic γ-aminobutyric acid structure represented by genera...
|
|
WO/2024/096066A1 |
The present disclosure provides a cyclic peptide derivative composition for treating or preventing central nervous system injury/disease. The present disclosure pertains to a composition comprising: a compound for treating or preventin...
|
|
WO/2024/059247A3 |
The present disclosure relates to methods of treating Alzheimer's disease, diseases and/or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance compr...
|
|
WO/2024/096461A2 |
The present invention relates to a therapeutic composition using a combined drug comprising, as active ingredients, colchicine or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof, for...
|
|
WO/2024/095158A1 |
Disclosed are uses of an orexin type 2 receptor (OX2R) agonist at non-awakening concentrations. Also disclosed are compositions and methods for administering an OX2R agonist to a subject (e.g., mammal) in need thereof at a dose that prov...
|
|
WO/2024/095199A1 |
The present invention relates to bacterial strains belonging to the genus Bifidobacterium and Lactobacillus, their combination, and their use in therapy, particularly for mood regulation and support of cognitive function. The invention a...
|
|
WO/2024/094731A1 |
The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormalit...
|
|
WO/2024/097164A1 |
Provided are methods of phosho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, and treatment. Novel p-tau sites, p-tau198, p-tau396, and p-tau...
|
|
WO/2024/097138A1 |
Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant or reduced protein expression, and therapeutic agents which can target the alternative splicing events in the genes can m...
|
|
WO/2024/095962A1 |
The present invention provides a novel pharmaceutical composition and a method for treating and/or preventing social impairment, such as autism spectrum disorder, fragile X syndrome, and/or autism spectrum-like symptoms. Specifically, pr...
|
|
WO/2024/093412A1 |
A heterocyclic compound, a preparation method therefor, and an application thereof. The structural formula of the heterocyclic compound is as represented by formula I. The present compound has excellent bioavailability, can improve cereb...
|
|
WO/2024/096644A1 |
The present invention relates to a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease, comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The present inventio...
|
|
WO/2024/095118A1 |
The present invention relates to dosing regimens of CSF-1R inhibitors for treating amyotrophic lateral sclerosis. More particularly, the present invention relates to a CSF-1R inhibitor for use in the treatment of amyotrophic lateral scle...
|
|
WO/2024/094156A1 |
Provided is a compound represented by formula (I), or a stereoisomer thereof, an optical isomer thereof, a solvate thereof, an isotope derivative thereof, or a pharmaceutically acceptable salt thereof. The compound can be used as a ligan...
|
|
WO/2024/095172A1 |
The present invention relates to prodrugs of compounds that contain vulnerable amines (e,g, secondary, tertiary and quaternary amines), and methods for their manufacture.
|
|
WO/2024/097387A1 |
The present invention provides compounds, compositions, and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.
|
|
WO/2024/044168A3 |
A method for treating a V-ATPase malfunction may include identifying a malfunction of at least apportion of a V-ATPase protein, where the malfunction occurs in a transmembrane portion of the V-ATPase protein. Further, the method may incl...
|
|
WO/2024/040103A3 |
The present invention relates to the discovery that various proteins are enriched in the amniotic fluid of fetuses with open neural tube defects (NTDs). The invention includes methods for the diagnosis of open NTD based upon the levels a...
|
|
WO/2024/097631A2 |
The present application relates to a method of treating pain, comprising: administering a therapeutically effective amount of triol to a subject to reduce symptoms of pain. The present application also relates to a method of treating dep...
|
|
WO/2024/097857A1 |
Methods of treating one or more eating disorders including anorexia nervosa, bulimia, and related clinical syndromes in a subject in need thereof are described. In some cases, electric stimulation and/or one or more active agents are are...
|
